In the demonstration, the optician recommends and demonstrates eyewear products that will enhance the customer's visual lifestyle and appearance. The customer is educated and has the opportunity, whenever possible, of experiencing the recommended product.
A glaucoma specialist explores endoscopic visualization for the diagnosis and treatment of uveitic-glaucoma-hyphema syndrome.
A fixed-dose combination containing an investigational rho kinase/norepinephrine transporter inhibitor and latanoprost 0.005% achieved its primary endpoint, showing potential as a high-efficacy, IOP-lowering therapy in a phase IIb trial.
A retrospective cohort study found a significantly higher rate of detection of nondiabetic retinopathy findings using ultra-widefield retinal imaging compared with nonmydriatic fundus photography.
Data from the phase III VISTA-DME trial show aflibercept 2 mg every 4 or every 8 weeks remains superior to laser photocoagulation and is associated with stable improvements in best-corrected visual acuity and macular thickness.
The symbols, signs, and abbreviations used every day in medical records have ancient roots in history.
Surgeons can take steps to manage an opaque bubble layer by reducing femtosecond laser spot line separation during LASIK flap creation.
Supraciliary micro-stent implantation can serve as a safe and effective stand-alone treatment in patients refractory to topical glaucoma therapy.
Although surgical intervention is not always necessary in eyes with choroidal detachment, drainage should be performed if spontaneous resolution does not occur in order to restore normal anatomy and prevent trabeculectomy failure.
Hydrogel punctal plugs may be a safe and viable method for delivery of anti-glaucoma drugs in the future.
The optimal time of implantation of a corneal inlay (Kamra, AcuFocus) to correct presbyopia in ametropic presbyopic patients seems to be 1 week after traditional LASIK in a planned two-stage KAMRA procedure.
Implantation of two stents (iStent, Glaukos) may be another option for controlling IOP in phakic and pseudophakic patients with open-angle glaucoma who are refractory to one anti-glaucoma medication.
Where leadership may once have been seen as crafting a master plan and handing down directives, today leadership manifests as a collaborative process.
Results of a randomized study show both superior and inferior visual field defects impair drivers’ performance on the computerized Hazard Perception Test. However, superior visual field loss is associated with significantly greater worsening than inferior visual field loss.
Selective laser trabeculoplasty provided a majority of Afro-Caribbean patients with a mean IOP reduction of 40% with no need for medical therapy.
An investigational glaucoma device that shunts aqueous from the anterior chamber to a sub-conjunctival/sub-Tenon’s pouch is being evaluated in a prospective study of 35 eyes operated on at two centers.
The outcomes for shunt implantation show promise as an option for the management of uveitic glaucoma. In a retrospective chart review, 73% of patients had a decrease of at least 20% in IOP 6 months postoperatively.
The electronic health records and electronic medical records implementations come with endless upgrades whether your clinic is prepared or not.
William Neusidl, MD, invents eyewear holder that attaches to slit lamp table, gives patients safe place for glasses
A corneal inlay improves near and intermediate vision with minimal compromise in distance acuity. Results are maintained over the long-term.
Nathan M. Radcliffe, MD, discusses use of laser technology for treating patients with early-stage glaucoma as an approach to decrease IOP or to reduce the need for IOP-lowering medications.
Several therapies are in the pipeline to treat Stargardt’s disease.
In this ongoing series of one-on-one interviews with key ophthalmic leaders, J.C. Noreika, MD, MBA, talks with Samuel Masket, MD, clinical professor of ophthalmology, David Geffen School of Medicine, Jules Stein Eye Institute, University of California, Los Angeles (UCLA). In his practice, Dr. Masket sees a high volume of patients referred for dysphototopsia and addresses issues related to the condition. Dr. Masket also highlights some of his many achievements and contributions to cataract and refractive surgery and tracks the field’s trends-from the infancy of phacoemulsification and lens implant cataract surgery to femtosecond lasers and extended depth-of-focus IOLs.
Observation of the episcleral venous fluid wave while performing canal-based glaucoma surgery provides intraoperative confirmation of accurate device placement, correlates with the extent of surgically induced canal cleavage, and may be a prognostic indicator for surgical success, said Ronald L. Fellman, MD.
The FDA has designated Dompé’s rhNGF (recombinant human nerve growth factor) as an orphan drug for the treatment of neurotrophic keratitis.
The FDA has issued 510(k) clearance to Nidek’s AL-Scan optical biometer.
Researchers from Massachusetts Eye and Ear, Harvard Medical School, and Boston University School of Medicine have found that the extent of retinal swelling due to cystoid macular edema (CME) was inversely related to dietary iodine intake in patients with retinitis pigmentosa (RP).
A new surgical advance-the Intrepid Balanced phacotips designed specifically for microcoaxial torsional ultrasound-has been found to have a significantly increased emulsification effect and markedly reduced shaft action compared with the traditional Kelman flared and mini-tips, said Khiun Tjia, MD.
Allergan has announced that, alongside its second-quarter financial results, it will reduce its workforce by about 1,500 employees-about 13% of its current global headcount-as part of efforts to boost stockholder value.
Bausch + Lomb has received 510(k) clearance from the FDA for its Victus femtosecond laser platform for laser-assisted lens fragmentation during cataract surgery.
